R&D channel feed

Scoop: Mer­ck scraps PhII tri­als of Alzheimer’s and de­pres­sion small mol­e­cule af­ter liv­er tox­i­c­i­ty ob­ser­va­tions

Last year
Pharma

Gri­fol­s' Alzheimer’s vac­cine ap­pears safe, but ef­fi­ca­cy un­clear, in PhII study

Last year

Im­mutep touts mid-stage da­ta for LAG-3 drug in first-line NSCLC, fi­nal­iz­ing plans for PhI­II test: #ES­MO23

Last year

Up­dat­ed: No­var­tis 'on track' to com­plete re­struc­tur­ing post San­doz spin, push­es back Plu­vic­to fil­ing

Last year
Pharma

Heard at #ES­MO23: No­var­tis and BeiGene fall­out; Now I know my AD­Cs; and a stand­ing ova­tion

Last year

New Plu­vic­to da­ta point to a po­ten­tial wider in­di­ca­tion, but No­var­tis leaves reg­u­la­to­ry time­line up in the air: #ES­MO23

Last year

BioN­Tech CAR-T man­u­fac­tur­ing change leads to fresh da­ta with vac­cine com­bo, with reg­is­tra­tional tri­al plans: #ES­MO23

Last year
Cell/Gene Tx
Manufacturing

How J&J’s Ry­bre­vant com­bo stacks up against As­traZeneca’s Tagris­so in EGFR-mu­tat­ed lung can­cer: #ES­MO23

Last year

Up­dat­ed: Verve plans first in-hu­man base edit­ing tri­al in the US af­ter FDA lifts clin­i­cal hold

Last year
Cell/Gene Tx

As­traZeneca, Dai­ichi Sankyo still need key over­all sur­vival re­sults on TROP2 ADC in breast, lung can­cer: #ES­MO23

Last year
Pharma

Merus touts bis­pe­cif­ic an­ti­body ef­fi­ca­cy da­ta with a lat­er da­ta cut-off in un­com­mon NRG1+ can­cers: #ES­MO23

Last year

You get an ADC, you get an ADC: Phar­mas bite on on­col­o­gy’s buzzi­est class

Last year
Deals
In Focus

Mi­rati and Am­gen un­wrap new KRAS tri­al da­ta, set­ting the stage for po­ten­tial com­bo treat­ments: #ES­MO23

Last year

Ear­ly da­ta on Dai­ichi Sankyo’s Mer­ck-part­nered ADC; As­traZeneca’s Da­to-Dxd com­bo; more from Seagen: #ES­MO23 roundup

Last year
Pharma

Roche de­tails Ale­cen­sa da­ta that may shift the drug to post-surgery ALK-pos­i­tive lung can­cer: #ES­MO23

Last year
Pharma

Pad­cev-Keytru­da sets new stan­dard in blad­der can­cer as Seagen and Astel­las move to­ward full ap­proval: #ES­MO23

Last year
Pharma

Eli Lil­ly re­veals two-year da­ta for ex­per­i­men­tal eczema treat­ment af­ter FDA road­block

Last year
Pharma
FDA+

Up­dat­ed: Am­gen spot­lights new ef­fi­ca­cy, safe­ty da­ta of mid-phase tar­latam­ab tri­al in hard-to-treat can­cer: #ES­MO23

Last year

J&J un­veils PhI­Ia da­ta of oral an­tivi­ral for dengue fever pre­ven­tion

Last year

Bris­tol My­ers un­corks pos­i­tive PhI­II read­out for sub­cu­ta­neous Op­di­vo

Last year
Pharma

Beam cuts 20% of staff, looks to part­ner on base-edit­ed CAR-T one month af­ter dos­ing first pa­tient

Last year
Cell/Gene Tx

Big Phar­mas part­ner with HBCU, with aim to cre­ate the largest African an­ces­try ge­nomics data­base

Last year
Pharma

Takeda's stem cell ther­a­py flunks PhI­II test study­ing the drug in Crohn's dis­ease

Last year

FDA ap­proves Mer­ck­'s Keytru­da for be­fore and af­ter lung can­cer surgery

Last year
FDA+
First page Previous page 64656667686970 Next page Last page
A service from the Financial Times